01228.HK
CANbridge Pharmaceuticals Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 1.92
−0.52%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 50.0M | 50.0M | 85.1M | 102.9M | 79.0M |
| Cost of Revenue | 13.4M | 13.4M | 30.8M | 38.7M | 30.1M |
| Gross Profit | 36.6M | 36.6M | 54.3M | 64.2M | 48.9M |
| Operating Expenses | |||||
| R&D Expense | 45.1M | 45.1M | 251.8M | 257.2M | 311.2M |
| SG&A Expense | 84.2M | 84.2M | 143.1M | 173.5M | 195.7M |
| General & Admin Expense | 36.8M | 36.8M | 68.2M | 89.8M | 108.9M |
| Selling & Marketing Expense | 47.4M | 47.4M | 74.9M | 83.7M | 86.8M |
| Other Expenses | — | — | — | (1.4M) | — |
| Total Operating Expenses | 129.3M | 129.3M | 394.8M | 429.3M | 506.9M |
| Cost and Expenses | 142.7M | 142.7M | 425.6M | 469.4M | 536.9M |
| Operating Income (EBIT) | (92.7M) | (92.7M) | (340.5M) | (366.5M) | (458.0M) |
| Non-Operating | |||||
| Interest Income | — | 362.4K | 508.0K | 11.0M | 3.9M |
| Interest Expense | 1.8M | 2.2M | 8.6M | 8.9M | 6.9M |
| Net Interest Income | (1.9M) | (1.8M) | (8.1M) | 2.0M | (3.0M) |
| Other Non-Op Income/Expense | 107.5M | 107.5M | (102.1M) | (12.3M) | (25.5M) |
| Non-Operating Income (excl Interest) | — | — | 94.2M | 3.3M | 27.1M |
| EBT (Pre-Tax Income) | 14.8M | 14.8M | (442.6M) | (378.8M) | (483.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | 14.8M | 14.8M | (442.6M) | (378.8M) | (483.5M) |
| Earnings from Cont. Ops | 14.8M | 14.8M | (442.6M) | (378.8M) | (483.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 14.8M | 14.8M | (442.6M) | (378.8M) | (483.5M) |
| Per Share | |||||
| Basic EPS | HK$0.05 | HK$0.03 | (HK$1.04) | (HK$0.89) | (HK$1.14) |
| Diluted EPS | HK$0.05 | HK$0.03 | (HK$1.04) | (HK$0.89) | (HK$1.14) |
| Revenue Per Share | HK$0.10 | HK$0.11 | HK$0.20 | HK$0.24 | HK$0.19 |
| Shares | |||||
| Basic Shares Outstanding | 477.0M | 456.9M | 424.8M | 424.4M | 424.2M |
| Diluted Shares Outstanding | 482.3M | 456.9M | 424.8M | 424.4M | 424.2M |
| Profitability Metrics | |||||
| EBITDA | (79.7M) | (79.0M) | (328.7M) | (341.4M) | (454.6M) |
| D&A | 13.0M | 13.7M | 11.8M | 28.5M | 22.0M |
| EBIT | (92.7M) | (92.7M) | (340.5M) | (369.9M) | (476.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025